GlassScriptPhysician profile
Amy C Sorrells
NPI 1326248162
$4,340.74
in general payments reported to CMS, 2019-2025
36 companies · $738 in 2025
The $738 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $203 · 2021: $761 · 2022: $934 · 2023: $617 · 2024: $713 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,838 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.42 |
| Education | $228.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.93 | 2019-2024 | Lo Loestrin Fe |
| Gynesonics, INC. | $403.03 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biogen, INC. | $380.98 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $299.97 | 2021-2025 | |
| Astellas Pharma US INC | $288.63 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $287.08 | 2019-2025 | Wegovy |
| Shield Therapeutics INC | $262.03 | 2023-2025 | Accrufer |
| Agile Therapeutics, INC. | $196.47 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $177.39 | 2019-2022 | |
| Organon LLC | $165.80 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $163.90 | 2019-2023 | Paragard T 380a |
| Exeltis, USA INC. | $107.29 | 2020-2022 | |
| Daiichi Sankyo INC. | $106.53 | 2019-2022 | |
| Millicent US INC | $100.16 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $100.16 | 2022-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $97.35 | 2021-2022 | |
| Lilly USA, LLC | $95.39 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $77.90 | 2019-2025 | |
| Evofem Biosciences, INC. | $55.50 | 2021-2022 | |
| Hologic Sales and Service, LLC | $53.43 | 2019-2024 | Aptima, Thinprep 2000 Processor, Third Wave |
| Sumitomo Pharma America, INC. | $53.03 | 2024 | Myfembree |
| Minerva Surgical, INC | $40.36 | 2022 | |
| Avion Pharmaceuticals | $36.67 | 2021 | |
| Olympus America INC. | $36.27 | 2019 | |
| Medtronic, INC. | $31.24 | 2021-2023 | Truclear |
| Takeda Pharmaceuticals U.S.A., INC. | $30.00 | 2022 | |
| Genzyme Corporation | $25.77 | 2022 | |
| Roche Diagnostics Corporation | $20.75 | 2021 | |
| Exact Sciences Corporation | $20.07 | 2023 | Cologuard Collection Kit |
| Aspira Women'S Health INC | $18.80 | 2022 | |
| Ascend Therapeutics US, LLC | $18.04 | 2020 | |
| Axonics, INC. | $17.78 | 2021 | |
| Dexcom, INC. | $17.25 | 2024 | Dexcom G6 Transmitter |
| Channel Medsystems, INC. | $16.03 | 2024 | |
| Allergan, INC. | $15.18 | 2020 | |
| Mylan Pharmaceuticals INC. | $14.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Sorrells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.